Foghorn TherapeuticsÂ Inc (FHTX) Peer Comparison

$4.92

$0.05 (1.03%)

As on 04-Sep-2026 19:53EDT

Market cap

$292 Mln

Revenue (TTM)

$37 Mln

P/E Ratio

--

P/B Ratio

2005.3

Div. Yield

0 %

Edit

	Foghorn TherapeuticsÂ Inc (FHTX)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Madrigal Pharmaceuticals (MDGL)
Market cap ($ Mln)	292	16,504	17,747	14,622	12,501
Revenue ($ Mln)	37	2,782	1,054	2,436	1,284
Net Profit ($ Mln)	-64.58	491.50	755.85	860.62	-325.10
Net Margin (%)	-175.78	17.67	71.69	35.33	-25.32
RoE (%)	--	110.09	--	42.98	-57.72
Price to Earnings	--	34.72	20.93	18.56	--
Price-To-Book	2,005.35	38.18	10.51	7.95	23.94

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	Foghorn TherapeuticsÂ Inc (FHTX)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Madrigal Pharmaceuticals (MDGL)
Operating Revenue	36.74	2,782.29	1,054.37	2,435.92	1,283.94
Cost of Revenue	21.04	1,982.07	103.47	85.67	109.42
Gross Profit	27.58	760.62	588.53	2,236.43	902.26
Operating Expenses	84.17	216.81	841.45	1,378.74	1,497.13
Operating Profit (EBIT)	-68.48	583.40	109.45	971.51	-322.62
Other Income	0.00	0.00	0.00	0.00	0.00
Profit before Tax	-64.58	598.92	101.11	1,035.47	-325.10
Provision for Tax	0.00	107.42	-654.74	174.84	0.00
Profit after Tax (Net Income)	-64.58	491.50	755.85	860.62	-325.10
Minority Interest	0.00	0.00	0.00	0.00	0.00
Consolidated Profit	0.00	0.00	0.00	0.00	0.00

Liabilities ($ Mln)

	Foghorn TherapeuticsÂ Inc (FHTX)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Madrigal Pharmaceuticals (MDGL)
Shareholder's Funds	-81.04	433.86	1,435.90	1,843.76	523.72
Minority Interest	0.00	0.00	0.00	0.00	0.00
Non-Current Liabilities	233.86	187.89	384.48	288.55	346.72
Current Liabilities	50.58	1,435.43	464.70	361.93	374.20
Total Liabilities	198.10	1,975.47	1,302.02	2,844.42	1,259.59

Assets ($ Mln)

	Foghorn TherapeuticsÂ Inc (FHTX)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Madrigal Pharmaceuticals (MDGL)
Non-Current Assets	33.35	1,006.90	895.24	1,243.41	45.47
Current Assets	170.05	1,050.29	1,389.84	1,250.82	1,199.18
Total Assets	198.10	1,975.47	1,302.02	2,844.42	1,259.59
Total Debt*	43.10	120.10	449.89	165.93	347.75
Net Current Assets	119.47	-385.14	925.52	888.90	824.98

Cashflow ($ Mln)

	Foghorn TherapeuticsÂ Inc (FHTX)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Madrigal Pharmaceuticals (MDGL)
Cash From Operating Activities	-86.10	713.22	51.77	884.27	-189.55
Cash Flow from Investing Activities	112.04	-31.14	-8.15	350.44	32.32
Cash from Financing Activities	1.02	-860.39	34.89	-969.59	255.98
Net Cash Inflow / Outflow	--	--	--	--	--

Ratios

Profitability Ratios

	Foghorn TherapeuticsÂ Inc (FHTX)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Madrigal Pharmaceuticals (MDGL)
ROCE (%)	196.45	53.56	-30.01	32.82	-31.49
ROE (%)	96.45	110.09	163.18	42.98	-57.72
ROA (%)	-23.15	15.64	31.68	29.32	-22.97
EBIT Margin (%)	-175.78	21.13	5.73	31.04	-18.97
Net Margin (%)	-175.78	17.67	71.69	35.33	-25.32
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

Growth Ratios

	Foghorn TherapeuticsÂ Inc (FHTX)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Madrigal Pharmaceuticals (MDGL)
Revenue Growth (%)	51.98	24.67	114.85	9.23	149.04
EBIT Growth (%)	14.35	18.70	136.39	-3.99	9.16
Net Profit Growth (%)	14.35	17.50	378.76	42.89	-15.32
EPS Growth (%)	18.18	26.84	353.27	50.42	-0.64
Book Value Growth (%)	5.74	164.02	816.12	-0.70	-42.66

Valuation Ratios

	Foghorn TherapeuticsÂ Inc (FHTX)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Madrigal Pharmaceuticals (MDGL)
Price / Earnings	-4.58	36.06	-59.76	15.79	-45.32
Price / Book Value	-3.13	35.44	-80.42	5.72	21.68
Dividend Yield (%)	--	--	--	--	--
EV/EBITDA	-3.14	28.08	-121.54	12.44	-47.02
Market Cap ($ Cr)	--	--	--	--	--

Solvency Ratios

	Foghorn TherapeuticsÂ Inc (FHTX)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Madrigal Pharmaceuticals (MDGL)
Debt to Equity	0.00	0.00	0.27	0.00	0.65
Short term debt to equity ratio	-0.03	0.00	0.05	0.00	0.00
Current Ratio	3.36	0.73	2.99	3.46	3.20
Quick Ratio	3.36	0.73	2.32	3.38	2.94
Interest Coverage	--	--	1.62	--	-9.32

Operating Efficiency Ratios

	Foghorn TherapeuticsÂ Inc (FHTX)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Madrigal Pharmaceuticals (MDGL)
Debtors to sales (%)	0.00	15.88	21.25	13.74	14.98
Asset Turnover	0.13	0.89	0.44	0.83	0.91
Receivable days	--	50.42	85.52	43.48	35.88
Inventory Days	--	--	1,056.70	96.17	354.23
Payable days	441.27	6.26	331.01	147.97	300.79
Cash Conversion Cycle	--	--	811.21	-8.32	89.33

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly